NHS Generic Pharmaceuticals - Clozapine
key details
| Value | £34,000,000 |
|---|---|
| Status | cancelled |
| Category (CPV) | 33600000 |
| Deadline | 19 Jan 2018 |
| Contract start | 1 Apr 2018 |
| Contract end | 31 Mar 2020 |
| Procedure | open |
| SME suitable | Yes |
| OCID | ocds-b5fd17-bf5ce11d-6ba0-47e5-b391-000fc3f570e5 |
description
NHS National Framework Agreement for Generic Pharmaceuticals - Clozapine.
documents
- https://www.contractsfinder.service.gov.uk/Notice/5de5dd69-f0ee-43d9-af33-ebf6053180f1 , tenderNotice
- https://www.contractsfinder.service.gov.uk/Notice/6d7dd187-ab28-4514-b4c4-b3396c9c3b87 , tenderNotice
Documents are linked, not mirrored. They are served by the publishing authority and may require registration.
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 19 Dec 2017 | Tender cancelled (tenderCancellation) | · | 6d7dd187-ab28-4514-b4c4-b3396c9c3b87-187842 |
more from NHS ENGLAND
- Products for the treatment of Haemophilia A · £215,000,000 · 11 May 2023
- NHS Framework Agreement for the supply of products for the treatment of Haemophilia A · £215,000,000 · 26 Apr 2023
- NHS Framework Agreement for the Supply of Human Normal Immunoglobulin & Anti-D Immunoglobulin · £526,598,540 · 3 Feb 2023
- NHS Framework Agreement for the supply of Adult Influenza Vaccines - Secondary Care · £16,000,000 · 22 Jul 2022
- National Framework Agreement for the supply of products for the management of Hereditary Angioedema · £74,500,000 · 5 Jul 2022
- NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema · £74,500,000 · 5 Jul 2022
- NHA National Framework Agreement for the supply of products for the treatment of Bleeding Disorders including Haemophilia B · £250,000,000 · 5 Jul 2022
- NHS National Framework Agreement for the supply of products for the treatment of Haemophilia A · £214,000,000 · 22 Mar 2022
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.